185122-74-1

Basic information

• Product Name: 1H-INDEN-1-AMINE, 5-BROMO-2,3-DIHYDRO-
• Synonyms: 5-BROMO-INDAN-1-YLAMINE;5-BROMO-2,3-DIHYDRO-1H-INDEN-1-AMINE;1H-INDEN-1-AMINE, 5-BROMO-2,3-DIHYDRO-;5-BROMO-2,3-DIHYDRO-1H-INDEN-1-AMINE HYDROCHLORIDE
• CAS NO: 185122-74-1
• Molecular Formula: C₉H₁₀BrN
• Molecular Weight: 212.09
• Mol File: 185122-74-1.mol
• Article Data: 22

Chemical Properties

• Boiling Point: 278.2±40.0 °C(Predicted)
• Appearance: /
• Density: 1.490±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C(protect from light)
• PKA: 9.05±0.20(Predicted)
• CAS DataBase Reference: 1H-INDEN-1-AMINE, 5-BROMO-2,3-DIHYDRO-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-INDEN-1-AMINE, 5-BROMO-2,3-DIHYDRO-(185122-74-1)
• EPA Substance Registry System: 1H-INDEN-1-AMINE, 5-BROMO-2,3-DIHYDRO-(185122-74-1)

Safety Data

• Hazardous Substances Data: 185122-74-1(Hazardous Substances Data)

Usage

General Description

1H-INDEN-1-AMINE, 5-BROMO-2,3-DIHYDRO- is a chemical compound with the molecular formula C9H10BrN. It is an amine derivative of 1H-indene, which is a bicyclic aromatic hydrocarbon. The presence of a bromine atom on the 5th position and a dihydro- group indicate that it is a brominated compound with a saturated ring structure. This chemical may have applications in organic synthesis, pharmaceutical research, or material science, but further research and testing would be necessary to determine its specific uses and properties.

Upstream product

• 701268-37-3 1-azido-5-bromo-2,3-dihydro-1H-indene 
• 1251457-83-6 5-bromo-indan-1-one oxime 
• 185122-63-8 5-bromo-2,3-dihydro-1H-inden-1-one oxime 
• 34598-49-7 5-Bromo-1-indanone 
• 34598-50-0 5-bromo-1-indanol 
• 158330-91-7 5-bromo-1-chloro-indane 

Downstream Products

• 903557-29-9 (S)-5-bromoindan-1-ylamine 
• 1299483-37-6 tert-butyl {5-[(1E)-3-oxo-3-({2,2,2-trifluoro-1-[3-(trifluoromethyl)phenyl]ethyl}amino)prop-1-en-1-yl]-2,3-dihydro-1H-inden-1-yl}carbamate 
• 1299483-38-7 (2E)-3-(1-Amino-2,3-dihydro-1H-inden-5-yl)-N-{2,2,2-trifluoro-1-[3-(trifluoromethyl)phenyl]-ethyl}acrylamide 
• 1299482-89-5 (2E)-3-(1-Acetamido-2,3-dihydro-1H-inden-5-yl)-N-{2,2,2-trifluoro-1-[3-(trifluoromethyl)-phenyl]ethyl}acrylamide 
• 1199829-00-9 benzyl 5-(hydroxymethyl)-2,3-dihydro-1H-inden-1-ylcarbamate 
• 1251457-86-9 benzyl 5-(chloromethyl)-2,3-dihydro-1H-inden-1-ylcarbamate 
• 1199828-99-3 methyl 1-(benzyloxycarbonylamino)-2,3-dihydro-1H-indene-5-carboxylate 
• 1199829-04-3 benzyl 5-((4-(hydroxymethyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)methyl)-2,3-dihydro-1H-inden-1-ylcarbamate 
• 1199828-95-9 N-(5-((4-(hydroxymethyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)methyl)-2,3-dihydro-1H-inden-1-yl)-2-methoxybenzenesulfonamide 
• 1199829-02-1 ethyl 1-((1-(benzyloxycarbonylamino)-2,3-dihydro-1H-inden-5-yl)methyl)-3-(trifluoromethyl)-1H-pyrazole-4-carboxylate 

Relevant articles and documents

Discovery of Aficamten (CK-274), a Next-Generation Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy

Hypercontractility of the cardiac sarcomere may be essential for the underlying pathological hypertrophy and fibrosis in genetic hypertrophic cardiomyopathies. Aficamten (CK-274) is a novel cardiac myosin inhibitor that was discovered from the optimization of indoline compound 1. The important advancement of the optimization was discovery of an Indane analogue (12) with a less restrictive structure-activity relationship that allowed for the rapid improvement of drug-like properties. Aficamten was designed to provide a predicted human half-life (t1/2) appropriate for once a day (qd) dosing, to reach steady state within two weeks, to have no substantial cytochrome P450 induction or inhibition, and to have a wide therapeutic window in vivo with a clear pharmacokinetic/pharmacodynamic relationship. In a phase I clinical trial, aficamten demonstrated a human t1/2 similar to predictions and was able to reach steady state concentration within the desired two-week window.

First Contact: 7-Phenyl-2-Aminoquinolines, Potent and Selective Neuronal Nitric Oxide Synthase Inhibitors That Target an Isoform-Specific Aspartate

Inhibition of neuronal nitric oxide synthase (nNOS), an enzyme implicated in neurodegenerative disorders, is an attractive strategy for treating or preventing these diseases. We previously developed several classes of 2-aminoquinoline-based nNOS inhibitor

DIHYDROBENZOFURAN AND INDEN ANALOGS AS CARDIAC SARCOMERE INHIBITORS

Provided are compounds of Formula (I), or a pharmaceutically acceptable salt thereof, wherein A, Z, B, R1, R2, R3, G1, G2, and G3 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt, thereof for use in methods of treatment heart diseases through cardiac sarcomere inhibtion.